Autotaxin (ATX) or ecto-nucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) is a secreted lysophospholipase D that generates the lipid mediator lysophosphatidic acid (LPA), a mitogen and chemo-attractant for many cell types. ATX-LPA signaling has roles in various pathologies including tumour progression and inflammation. However, the molecular basis of substrate recognition and catalysis, and the mechanism of interaction with target cells, has been elusive. Here we present the crystal structure of ATX, alone and in complex with a small-molecule inhibitor. We identify a hydrophobic lipid-binding pocket and map key residues required for catalysis and selection between nucleotide and phospholipid substrates. We show that ATX interacts with cell-surface integrins via its N-terminal somatomedin-B-like domains, using an atypical mechanism. Our results define determinants of substrate discrimination by the ENPP family, suggest how ATX promotes localized LPA signaling, and enable new approaches to target ATX with small-molecule therapeutics.

Abstract. Proteins in the TGF-[~ superfamily transduce their effects through binding to type I and type II serine/threonine kinase receptors. Osteogenic protein-1 (OP-1, also known as bone morphogenetic protein-7 or BMP-7), a member of the TGF-[3 superfamily which belongs to the BMP subfamily, was found to bind activin receptor type I (ActR-I), and BMP receptors type IA (BMPR-IA) and type IB (BMPR-IB) in the presence of activin receptors type II (ActR-II) and type liB (ActR-IIB). The binding affinity of OP-1 to ActR-II was two-to threefold lower than that of activin A. A transcriptional activation signal was transduced after binding of OP-1 to the complex of ActR-I and ActR-II, or that of BMPR-IB and ActR-II. These results indicate that ActR-II can act as a functional type II receptor for OP-1, as well as for activins. Some of the known biological effects of activin were observed for OP-1, including growth inhibition and erythroid differentiation induction. Compared to activin, OP-1 was shown to be a poor inducer of mesoderm in Xenopus embryos.Moreover, follistatin, an inhibitor of activins, was found to inhibit the effects of OP-1, if added at a 10-fold excess. However, certain effects of activin, like induction of follicle stimulating hormone secretion in rat pituitary cells were not observed for OP-1. OP-1 has overlapping binding specificities with activins, and shares certain but not all of the functional effects of activins. Thus, OP-1 may have broader effects in vivo than hitherto recognized.

Pituitary cell aggregates prepared from 14-day-old male or female rats and maintained for 4-5 days in culture were superfused with LHRH during periods of 20 or 90 min. LHRH provoked a rapid and sustained rise of PRL release at concentrations similar to those stimulating LH release (10(-11)-10(-8) M). Dopamine, at a concentration inhibiting PRL release for 90%, weakened but did not prevent this stimulation. LHRH also stimulated PRL release in aggregates prepared from adult male rat pituitary cells, but the effect was weaker and seen only after a more prolonged period in culture. There was no PRL response to LHRH in aggregates of lactotroph-enriched populations, obtained by gradient sedimentation at unit gravity, in which only few and small gonadotrophs are present. When a lactotroph-enriched/gonadotroph-poor population was coaggregated with a highly enriched population of large gonadotrophs, LHRH very effectively stimulated PRL release, the extent of stimulation being dependent on the proportional number of gonadotrophs in the coculture. Superfusion of lactotroph-enriched/gonadotroph-poor aggregates with medium in which the gonadotroph-enriched aggregates had previously been incubated for 3 h with 1 nM LHRH (gonadotroph-conditioned medium) also provoked a clear-cut rise in PRL release. This effect was not due to LH, FSH, or the small amounts of PRL present in the gonadotroph-conditioned medium. The LHRH antagonist [D-Phe2-D-Ala6]LHRH was capable of blocking the PRL response to LHRH but not that to the gonadotroph-conditioned medium. In the lactotroph-gonadotroph coaggregates TRH stimulated PRL release but had no effect on LH release. TRH was also ineffective in releasing LH or FSH in populations containing both gonadotrophs and thyrotrophs. The present data suggest that gonadotrophs can activate the secretory activity of the lacotrophs through the release of a paracrine humoral factor.

Ectonucleotide pyrophosphatase/phosphodiesterase-1 (NPP1) converts extracellular nucleotides into inorganic pyrophosphate, whereas its close relative NPP2/autotaxin hydrolyzes lysophospholipids. NPP1 regulates calcification in mineralization-competent tissues, and a lack of NPP1 function underlies calcification disorders. Here, we show that NPP1 forms homodimers via intramembrane disulfide bonding, but is also processed intracellularly to a secreted monomer. The structure of secreted NPP1 reveals a characteristic bimetallic active site and a nucleotide-binding groove, but it lacks the lipid-binding pocket and open tunnel present in NPP2. A loop adjacent to the nucleotide-binding site, which is disordered in NPP2, is well ordered in NPP1 and might promote nucleotide binding. Remarkably, the N-terminal somatomedin B-like domains of NPP1, unlike those in NPP2, are flexible and do not contact the catalytic domain. Our results provide a structural basis for the nucleotide pyrophosphatase activity of NPP1 and help to understand how disease-causing mutations may affect NPP1 structure and function.

No abstract